Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  TORC1/2 inhibitor MLN0128
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C31001, NCI-2014-00386, NCT02049957
TORC1/2 inhibitor INK128 in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-143, NCI-2014-00779, NCT02091531
TORC1/2 Inhibitor MLN0128 in Treating Patients with Stage IV or Recurrent Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9780, NCI-2015-00545, 2015-00500, NCT02417701
Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C32001, NCI-2014-01567, 2013-000466-11, NCT01899053
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-079, NCI-2014-01118, 9552, NCT02142803
MLN0128 and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0665, NCI-2014-01107, 9585, NCT02159989
Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Supportive care
Age: 18 and over
Trial IDs: C31002, NCI-2014-01846, U1111-1156-4099, NCT02197572
TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1301, NCI-2014-00907, NCT02133183
Start Over